Company news
Plus Therapeutics, Inc. news in 2025
Plus Therapeutics, Inc.'s news releases, calls and decks from 2025, newest first.
Plus Therapeutics Expands CNSide Assay Platform to State of California
December 11, 2025
Plus Therapeutics Announces Expansion of CNSide Team and Issuance of Inducement Grants
December 9, 2025
Plus Therapeutics Highlights Three REYOBIQ™ Clinical Data Presentations at 2025 WFNOS/SNO Annual Meeting
December 4, 2025
Plus Therapeutics to Present ReSPECT Phase 1 Dose Escalation Study Results for Leptomeningeal Metastases at the 2025 San Antonio Breast Cancer Symposium
December 1, 2025
Plus Therapeutics Announces Completion of U.S. FDA Meeting on Future Clinical Development Plans for REYOBIQ™ in Leptomeningeal Metastases
November 24, 2025
Plus Therapeutics Secures National Coverage Agreement with Humana for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer
November 20, 2025
Plus Therapeutics Granted 180-Day Extension to Regain Compliance with Nasdaq’s Minimum Bid Price Requirement
November 17, 2025
Plus Therapeutics Highlights ReSPECT-LM Clinical Trial Results at 40th SITC Annual Meeting, Melanoma Research Foundation Brain Metastases Summit 4.0
November 6, 2025
Plus Therapeutics Reports Third Quarter Financial Results and Recent Business Highlights
October 30, 2025
Plus Therapeutics Updates on CNSide® Diagnostic Platform Launch
October 21, 2025
Plus Therapeutics Announces National Coverage Agreement with UnitedHealthcare Insurance Company for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer
September 25, 2025
Plus Therapeutics Announces Additional $1.9 Million Advance Payment from CPRIT
September 22, 2025
Plus Therapeutics Announces Successful Accreditation and Certification for Its CNSide® Diagnostics Clinical Laboratory
September 18, 2025
Plus Therapeutics to Participate in Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference
September 2, 2025
Plus Therapeutics Regains Compliance with Applicable Nasdaq Listing Criteria
August 26, 2025
Plus Therapeutics Presents Positive ReSPECT-LM Clinical Trial Results of REYOBIQ™ in Leptomeningeal Metastases
August 18, 2025
Plus Therapeutics Reports Stockholders’ Equity in Excess of $2.5 million in Compliance with Nasdaq Equity Requirements
August 15, 2025
Plus Therapeutics Reports Second Quarter Financial Results and Recent Business Highlights
August 14, 2025
Plus Therapeutics Presents Positive CNSide CSF Assay Platform Results at the 2025 SNO/ASCO CNS Metastases Conference
August 14, 2025
Plus Therapeutics Provides US Launch Update for its CNSide® Diagnostic
July 31, 2025
Plus Therapeutics Announces $1.6 Million Advance Payment from CPRIT
July 23, 2025
Plus Therapeutics Presents ReSPECT-LM Clinical Trial Results for REYOBIQ™ in Patients with Leptomeningeal Metastases
July 15, 2025
Plus Therapeutics Announces Two CNSide Presentations at the Upcoming SNO/ASCO CNS Metastases Conference
July 10, 2025
Plus Therapeutics Announces Initial Patients Successfully Treated in ReSPECT-LM Dose Optimization Trial for REYOBIQ™ in Leptomeningeal Metastases
July 8, 2025
Plus Therapeutics Announces FDA Agreement to Initiate ReSPECT-LM Dose Optimization Trial for REYOBIQ™ in Leptomeningeal Metastases
June 30, 2025
Plus Therapeutics Provides Business Update on CNSide Diagnostics Subsidiary
June 26, 2025
Plus Therapeutics to Provide Business Update and Host Conference Call on Thursday, June 26, 2025 at 9: 00 A.M. ET
June 25, 2025
Plus Therapeutics Announces FDA Clearance of its Investigational New Drug Application using REYOBIQTM for the Treatment of Childhood Brain Cancer
June 25, 2025
Plus Therapeutics Announces Comprehensive Restructuring of $15 Million March 2025 Equity Financing
June 24, 2025
Plus Therapeutics Reports First Quarter Financial Results and Recent Business Highlights
May 30, 2025
Plus Therapeutics, Inc. Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Quarterly Report on Form 10-Q
May 23, 2025
Plus Therapeutics’ REYOBIQ™ Shows Clinical Benefit and Safety in the ReSPECT-LM Clinical Trial for Patients with Leptomeningeal Metastases (LM)
May 14, 2025
Plus Therapeutics to Participate in the D. Boral Capital Inaugural Global Conference
May 8, 2025
Plus Therapeutics Announces Biotech Industry Veteran Kyle Guse Joins its Board of Directors
April 23, 2025
Plus Therapeutics Presents New Data Highlighting Clinical Benefit and Safety of REYOBIQ in the ReSPECT-LM Clinical Trial for Patients with Leptomeningeal Metastases
April 15, 2025
Plus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
March 27, 2025
Plus Therapeutics Introduces REYOBIQ™, FDA-Accepted Proprietary Name for Lead Drug Candidate
March 20, 2025
Plus Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 27, 2025
March 19, 2025
Plus Therapeutics Regains Compliance with Nasdaq Minimum Stockholders’ Equity Requirement
March 10, 2025
Plus Therapeutics Announces Peer-Reviewed Publication in Nature Communications Highlighting Promising Phase 1 Results for Rhenium (186Re) Obisbemeda in Glioblastoma
March 7, 2025
Plus Therapeutics Granted U.S. FDA Orphan Drug Designation for Rhenium (186Re) Obisbemeda for the Treatment of Leptomeningeal Metastases in Patients with Lung Cancer
March 6, 2025
Plus Therapeutics Announces New Employment Inducement Grants
March 5, 2025
Plus Therapeutics Secures Private Placement of Approximately $15 Million in Gross Proceeds
March 4, 2025
Plus Therapeutics Advances Lead Drug Rhenium (186Re) Obisbemeda for Patients with Leptomeningeal Metastases
February 26, 2025
Plus Therapeutics Announces Leadership Appointments for its CNSide Diagnostics Subsidiary
February 24, 2025
Plus Therapeutics Appoints Dr. Michael Rosol as Chief Development Officer
February 20, 2025
Plus Therapeutics Secures $5.7 Million Financing to Support Leptomeningeal Metastases Program
February 18, 2025